Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Zymeworks ( (ZYME) ).
Zymeworks Inc. announced the appointment of Oleg Nodelman to its board of directors, continuing its board renewal process. Nodelman, founder of EcoR1 Capital and a seasoned expert in biotech investment, is expected to bring valuable insights to Zymeworks as it advances its strategic goals and enhances its position within the biotechnology industry.
More about Zymeworks
Zymeworks Inc. is a global clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of novel, multifunctional biotherapeutics. It aims to improve the treatment of challenging conditions such as cancer, inflammation, and autoimmune diseases through its innovative therapeutic platforms and integrated drug development engine. The company has developed zanidatamab, a HER2-targeted bispecific antibody, and has entered into strategic partnerships for its development and commercialization.
YTD Price Performance: 1.56%
Average Trading Volume: 446,024
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.04B
See more data about ZYME stock on TipRanks’ Stock Analysis page.
